使用西地那非治疗与间质性肺疾病相关的肺动脉高压。
The use of sildenafil to treat pulmonary hypertension associated with interstitial lung disease.
机构信息
Royal Brompton Hospital, London, UK.
出版信息
Respirology. 2010 Nov;15(8):1226-32. doi: 10.1111/j.1440-1843.2010.01860.x.
BACKGROUND AND OBJECTIVE
Limited data suggest a benefit following sildenafil treatment in patients with pulmonary hypertension (PH) and interstitial lung disease (ILD). The role of sildenafil in the management of PH in ILD is not clear. We report our experience of ILD patients with PH after 6-month sildenafil therapy.
METHODS
We reviewed 15 patients (mean age 55 ± 15 years; 8 men) with ILD (mean FVC 52.6 ± 15.4%) and PH (mean right ventricular systolic pressure 73.8 ± 17.8 mm Hg). Median brain natriuretic peptide: 37 (5-452) pmol/L; mean 6MWD: 156 ± 101 m.
RESULTS
Following 6-month treatment with sildenafil, brain natriuretic peptide levels were lower (n = 12, P = 0.03), 6MWD was higher (n = 6, P < 0.05), but no change in right ventricular systolic pressure (n = 11) was demonstrated.
CONCLUSIONS
Our observations suggest that sildenafil may be useful in the management of PH in ILD. Controlled trials are warranted before therapeutic recommendations can be made.
背景和目的
有限的数据表明，在患有肺动脉高压（PH）和间质性肺病（ILD）的患者中，西地那非治疗有获益。西地那非在ILD 患者 PH 管理中的作用尚不清楚。我们报告了我们在使用西地那非治疗 6 个月后 PH 合并 ILD 患者的经验。
方法
我们回顾了 15 名患有 ILD（平均 FVC 52.6 ± 15.4%）和 PH（平均右心室收缩压 73.8 ± 17.8mmHg）的患者（平均年龄 55 ± 15 岁；8 名男性）。中位脑利钠肽：37（5-452）pmol/L；平均 6MWD：156 ± 101m。
结果
在接受西地那非 6 个月治疗后，脑利钠肽水平降低（n = 12，P = 0.03），6MWD 升高（n = 6，P < 0.05），但右心室收缩压无变化（n = 11）。
结论
我们的观察结果表明，西地那非可能对 ILD 合并 PH 的治疗有用。在提出治疗建议之前，需要进行对照试验。
Zotero 插件